Atricure CTO Salvatore Privitera sells $407,557 in stock By Investing.com

Salvatore Privitera, Chief Technical Officer at AtriCure, Inc. (), sold shares of the company’s common stock totaling $407,557 on September 2, 2026.

Mr. Privitera disposed of 7,763 shares at a price of $52.50 per share. These shares were sold pursuant to a 10b5-1 trading plan, which was adopted on February 20, 2026. Following this transaction, Mr. Privitera directly holds 150,921 shares of AtriCure common stock.The sale comes as AtriCure shares trade near their 52-week high of $53.50, having surged 107% from their 52-week low. According to InvestingPro analysis, the stock appears overvalued relative to its Fair Value—placing it among candidates for the platform’s Most Overvalued list. The company maintains a “GREAT” financial health score of 3.33.

In other recent news, AtriCure Inc. reported second-quarter 2026 earnings that exceeded Wall Street expectations. The company posted adjusted earnings of $0.18 per share, surpassing analysts’ projections of a $0.01 loss. Revenue also rose to $153.6 million, beating the expected $151.84 million. Despite these positive results, the stock experienced a decline in after-hours trading due to a cautious outlook for the remainder of the year. Additionally, several analyst firms have adjusted their price targets for AtriCure. Needham raised its target to $64, maintaining a Buy rating, based on the company’s BoxX-NoAF trial. Piper Sandler increased its target to $60, highlighting a new quality measure introduced by the Society of Thoracic Surgeons. Similarly, BTIG raised its target to $55, citing the same quality metric as a potential driver for AtriCure’s Open Ablation products.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.